Ultromics selected for the Tech Nation’s Future Fifty 2025 programme

Meet the Future Fifty companies: https://technation.io/future-fifty-2025-cohort-2/

Oxford, UK, September 11, 2025 - Ultromics has been named to the UK’s Future Fifty 2025 programme, joining the country’s most prestigious initiative for scaling tech companies. Delivered by Tech Nation and Founders Forum in partnership with HSBC Innovation Banking, the programme has supported more than 30 UK-founded unicorns that have collectively raised over £16 billion, including alumni like Revolut, Skyscanner, Monzo, and Deliveroo.

Ultromics’ inclusion was officially announced today at the Future Fifty Forum at Daylesford Farm in the Cotswolds.

Ultromics’ mission is to close one of the biggest diagnostic gaps in healthcare:      undiagnosed heart failure. The company has pioneered the use of AI in cardiovascular imaging and has a proven track record of translating cutting-edge research into clinical practice. Founded out of the University of Oxford, Ultromics set out to tackle the silent crisis of late or missed diagnosis, which leaves millions without timely treatment.

Built on one of the world’s largest echocardiography datasets and validated in over 25 peer-reviewed studies, Ultromics developed EchoGo®, the first FDA-cleared and Medicare-reimbursed AI platform for detection of complex cardiac diseases. Today, the platform has processed more than 400,000 patient cases, is cited in leading government association guidelines, and is already in use across flagship institutions including Mayo Clinic, Northwestern Medicine, and University Hospitals Cleveland. With support from a $55 million Series C raise, the company is accelerating its U.S. expansion and scaling its mission to make earlier detection of heart disease a routine part of patient care worldwide.

Ross Upton, CEO and Founder of Ultromics, said: “It’s an honour to be selected for the Future Fifty programme and to join a community of companies helping shape the future of UK tech. This recognition reflects the incredible progress our team has made and the growing impact of AI in transforming healthcare. We’re entering the next phase of growth, scaling our technology to reach more clinicians and patients, and helping redefine how heart disease is detected and treated.”

Find out more about Ultromics' AI here.

“It’s an honour to be selected for the Future Fifty programme and to join a community of companies helping shape the future of UK tech. This recognition reflects the incredible progress our team has made and the growing impact of AI in transforming healthcare. We’re entering the next phase of growth, scaling our technology to reach more clinicians and patients, and helping redefine how heart disease is detected and treated.”